Are direct-acting antivirals for the treatment of hepatitis C virus (HCV) more effective than peginterferon alfa and ribavirin (PEG/riba)? Researchers employed a generalized cost-effectiveness analysis (GCEA) to find out. Results confirmed that direct-acting antivirals are cost-effective and that emphasis should be placed on the importance of incorporating GCEA into decision-making with regard to treating HCV.

Reference: Chou JW, Graf M, Díaz Espinosa O, Brewer I, Heim Z, Baumgardner J. Generalized cost-effectiveness analysis to assess treatment value in hepatitis C. Am J Manag Care. 2023 Dec;29(12):696-703. doi: 10.37765/ajmc.2023.89468. PMID: 38170486.